Agios Pharmaceuticals | AGIO - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.84B 205M 2026-09
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
Arrowhead Research USD 46.63M 4.88M 2026-06
Astellas Pharma JPY 215.29B 225M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Bayer EUR 4.02B 53M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Daiichi Sankyo JPY 237.75B 12.21B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Exelixis USD 154.56M 6.93M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Merck USD 2.86B 25M 2026-09
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.08B 163M 2026-09
Novartis USD 3.08B 58M 2026-09
Pfizer USD 3.28B 132M 2026-09
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09